Botulinum toxin-A in postoperative pediatric stiff hips  by Awaad, Yasser et al.
Journal of Taibah University Medical Sciences (2013) 8(3), 187–191
Taibah University
Journal of Taibah University Medical Sciences
www.sciencedirect.comCase Report
Botulinum toxin-A in postoperative pediatric stiﬀ hips
Yasser Awaad, MD a, Tamer Rizk, FRCPCH a,*, AlShahid Ahmed Abak, MD b,
Kazi Kabiruddin, MD b and Khalid I. Khoshhal, ABOS c
aNational Neuroscience Institute, King Fahad Medical City, Riyadh, Kingdom of Saudi Arabia
bOrthopedic Surgery Division, King Fahad Medical City, Riyadh, Kingdom of Saudi Arabia
cOrthopedic Department, Taibah University, Almadinah Almunawwarah, Kingdom of Saudi Arabia









Objective: The aim of the study is to show the functional contribution of botulinum toxin-A in the treatment of postoperative
pediatric stiff hips.
Methods: Four pediatric patients with postoperative stiff hips were included. Three patients with complicated developmental
dysplasia of the hip after multiple revision surgeries, and a case of cerebral palsy after hip surgery were given botulinum toxin injec-
tions in selected muscles as an adjunctive therapy to the standard orthopedic and rehabilitation management.
Results: All patients experienced a significant reduction in pain with a significant improvement in posture, range of motion and
mobility.
Conclusion: The preliminary results of botulinum toxin-A injection when given to selected muscles seem to be promising in
relieving pain and improving range of motion in pediatric patients with postoperative stiff hips. It may be considered as an option
in the treatment of difficult cases of postoperative stiff hips refractory to physiotherapy.
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Figure 1: Case 1; Pelvic X-ray showing dislocation of the right hip
in hip spica cast, four weeks postoperatively.
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Acquired hip stiffness in pediatric age group can be quite a
challenging task for rehabilitation. Its causes include trauma
surgery, immobilization, infections, Perthes’ disease, cerebra
palsy (CP), slipped capital femoral epiphysis, idiopathic chon-
drolysis and others.
Postoperative stiffness is a disabling and frustrating surgi-
cal complication for both patient and surgeon.1 Persistent
postoperative stiffness remains difficult to treat in some pa-
tients and require different interventions.
Temporary reduction in hip range of motion is frequently
seen after surgical treatment of Developmental Dysplasia of
the Hip (DDH), which usually responds to stretching exercises
Nevertheless, reduction in range of motion and stiffness is
more severe after redo or revision surgery especially if surgery
was repeated several times, which means prolonged casting as
well.2–4 Revision cases are difficult to treat and need an expert
team for management.3,4
The reported hip problems in CP are relatively frequent
(25–75%).5 They include progressive subluxation, dislocation
stiffness and pain.6,7 These occurred because of spastic muscle
forces acting on the femoral head in the acetabular cavity.5
Botulinum toxin-A (BoNT-A) as a neuromuscular blocker is
used widely in different medical specialties including orthopedics
Jo´z´wiak et al.8 reported the usefulness of targeted intramuscular
injection of BoNT-A to prevent neurogenic hip dislocation in chil-
drenwith spasticCP. In fact theuseofBoNT-Awas reportedmuch
earlier in 1988, but the first published report for orthopedic usewas
in 1993. However, it was licensed only in Switzerland until around
2007.8–10 Now, BoNT-A injection has been established as an alter-
native therapy in cases of muscle hyperactivity to achieve early
mobilization and to control pain.5 It also helps in improving
the personal hygiene and rehabilitation.11
Targeted BoNT-A is a well-tolerated anti-spasticity treat-
ment. It produces short term chemical denervation, which re-
duces muscle contractility by inhibiting presynaptic release of
acetylcholine in a dose dependent fashion.12,13 Consequently
it relieves muscle spasm related to pain from musculoskeleta
origin.12,14,15 The effect of BoNT-A injection lasts for
3–6 months, which gives a long term improvement to allow
other treatments to take place.12
The current study aims to present the results of the use of
BoNT-A in the treatment of postoperative acquired hip stiff-
ness in children that is refractory to standard physiotherapy.
Case 1
A 38-month-old girl noticed to have an abnormal gait and
diagnosed as a case of bilateral DDH. One stage bilateral open
reduction without acetapuloplasty was performed in another
institute at the age of 26 months. Follow up X-ray after four
weeks showeddislocated righthip in the spica cast (Figure 1). Revi-sion surgery was done in our institute, twice for redislocation,
which included acetabuloplasty and femoral osteotomy. She
had a fracture distal femur in between. The total casting was
around 28 weeks. A significant decrease in range of motion was
noticed in both hips and the patient was walking with a limp
and hyperlordosis. Hip flexion was only from 40 to 90 degrees
and abduction, adduction, and rotation were not more than 20
degrees each. Extensive physiotherapy was started but did not
show a significant improvement. Decision was taken to admit
the patient for rehabilitation and BoNT-A injection (BOTOXR,
Allergan Inc., Irvine, CA 92623, USA) in the quadriceps, the
hip adductors and the Sartorius muscle (100 units in each mus-
cle). She showed a marked improvement with her range of move-
ments, spasm, pain and limping that started at two weeks post
injection and continued till in her last follow up (Table 1).
Case 2
A four-year-old female was diagnosed to have bilateral DDH
at the age of 16 months. At the age of 2 years she had bilateral
hip surgery in form of anterior open reduction and Pember-
ton’s acetabuloplasty (Figure 2). She had two revision hip sur-
geries for redislocation of both hips at two settings with a total
casting of 24 weeks. With the removal of the last cast, both
hips were manipulated under anesthesia and the patient was
referred for an extensive physical therapy program (Figure
3). The flexion in the right hip was from 30 to 90 and in the left
10–90 degrees with very limited rotation and abduction. At
three months she was assessed again in the clinic for hip range
of motion. She had only gained 110 degrees of flexion, and
around 20 degrees of abduction and rotation on either side.
BoNT-A injection therapy (100 units in the quadriceps,
100 units in the hip adductors and 100 units in the Sartorius
muscle), which decreased stiffness in both hips; this facilitated
physiotherapy and rehabilitation measures that improved her
Table 1: Pain and spasticity before and after injection.
Patient Pain scale before injection Pain scale after injection MAS* before injection MAS after injection
R L R L
#1 9 1–2 4 4 1 1
#2 9 1–2 3 4 1 1
#3 8–9 1–2 N 4 N 1
#4 8 1–2 4 2 1 1
* MAS: Modified Ashworth Scale. 0 = No increase in muscle tone, 1 = Slight increase in the muscle tone, manifested by catch and release or
minimal resistance at the end of the range of motion, 2 = more marked increase in the muscle tone through most of the range of motion, but
affected parts are easily moved, 3 = considerable increase in the muscle tone, and passive movements are difficult, 4 = affected parts are rigid in
flexion or extension.16
Figure 2: Case 2; Postoperative pelvic X-ray showing both hips
after bilateral open reduction and Pemberton’s acetabuloplasty.
Figure 3: Case 2; Pelvic X-ray six weeks post cast removal showing
bilateral concentric reduction of both hips but hips were stiff.
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was carried out in form of open reduction, acetabuloplasty
and femoral shortening osteotomy. Three months post opera-
tion the hip spica cast was removed. Left hip was found in
fixed flexion (80 degrees), abduction and external rotation
deformity. She started to walk with a clear limp and a lordotic
gait. She was subjected to extensive in-patient followed by out-
patient physical therapy program. Due to failure in gaining
significant range of motion, the left hip flexors and adductors
were released surgically. However optimum results were not
achieved. Subsequently BoNT-A injection was given (100 units
in the quadriceps, 100 units in the hip adductors and 100 units
in the Sartorius muscle). This was followed by extensive phys-
ical therapy that resulted in an improvement in range of mo-
tion. It was also proved to be beneficial in decreasing the
limp, pelvic obliquity and spinal deviation (Table 1). Slight
limitation of flexion and internal rotation (10–15 degrees)
was observed at the left hip in the last follow up.
Case 4
A 17-year-old female; known to have diplegic CP presented
with right hip pain and limping. She was seen at the movement
disorders clinic for spasticity management, she had leg length
discrepancy and pain in the right hip. She was diagnosed with
right hip severe subluxation, for which she had right hip Chiari
osteotomy. After surgery she had severe muscle spam, pain
and spasticity in the right lower extremity much more than
the left side and more than before surgery. BoNT-A injection
was given twice, six months apart (100 units in the quadriceps,
100 units in the adductors, and 100 units in the hamstring mus-
cles). She had an improvement in spasticity, pain and in her
gait. In the last follow up visit she was using a cane to assist
her in long distance walking but she was pain free with equal
hip range of motion (Table 1).
Methods
Four patients with postoperative hip stiffness that was refrac-
tory to extensive physiotherapy program were included in the
study after obtaining informed consent from the parents to go
through the trial of BoNT-A treatment. The four patients in-
cluded were two patients with post revision open hip reduction
for DDH and prolonged casting, one older patient with DDH
that had three simultaneous procedures and one older patient
with CP post hip surgery for subluxation. They all had an exten-
sive physiotherapy program that was for more than six weeks atrange of motion to near normal in the last follow up at the age
of 4 years (Table 1).
Case 3
A seven-year-old female diagnosed with left DDH at an early
age and was offered treatment but refused by parents. At
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between the pediatric neurologist and the physiotherapist.Mod-
ified Ashworth Scale (MAS) in children with spasticity was used
to assess muscle tightness before and after injection (Table 1).16
All injections were given by an expert in the treatment with
BoNT-A (the first author). Patients were examined after the
injections for signs of adverse reaction to the toxin. Parents
were asked to report back if any of the complications occurred
later. Patients were referred back to physiotherapy department
to continue their rehabilitation program. The pain severity was
assessed on a standardized Color Analog Scale (in case of chil-
dren below 6 years the mother was asked to answer), which is a
validated scale (Table 1).17,18
Results
All four patients experienced a significant reduction in pain
with a significant improvement in posture, range of motion
and mobility. All patients showed an improvement at 2 weeks
period (max effect of the Botox). No serious complications
were reported that were directly related to the use of BoNT-
A treatment. The three DDH cases needed single dose injection
to get the desired outcome whereas the fourth CP patient
needed repeated injections (two doses) to get the desired out-
come, probably due to her original spasticity. She showed an
improvement after 2 weeks, but she has to be injected after
6 months because the wearing off of the effect of the Botox.
All muscles injected matched the clinical presentation (Table 1).
Discussion
There are multiple options for treatment of a postoperative
stiffness: physiotherapy, manipulation under anesthesia and
surgical debridement or releases,19 the gain in the range of mo-
tion with physiotherapy is often modest. The surgeon can
forcefully overcome adhesions with manipulation under anes-
thesia, while moving the joint through the desired range of mo-
tion paying attention to exert enough force to move the joint
and not enough to fracture the already weakened bone by long
immobilization and reduced mobility. In refractory cases sur-
gical release of adhesions often is used.19 In all our cases we
started with an extensive physiotherapy program, case 2 had
manipulation under anesthesia and case 3 had surgical re-
leases. These measures did not help and they had refractory
postoperative stiffness that led us to explore more options
for treatment. As a multiple disciplinary team in our spasticity
clinic, which includes pediatric neurologist, pediatric orthope-
dic surgeon, pediatric rehabilitation medicine, pediatric physi-
cal therapist and others, and as the experience with BoNT-A
injection is well established in our center; the idea of using
BoNT-A injection came out, knowing its safety and effective-
ness even after repeated injections.13,20,21
BoNT-A has been used to decrease postoperative spasticity
related pain22 and in postoperative contractures in cases post
total knee and total hip arthroplasty.21,23 It has been shown
that the chemical denervation effect of BoNT-A leads to tem-
porary paralysis that relieves muscle over activity, which is a
direct cause of muscle shortening and the decrease in range
of motion.24
The presented cases showed that BoNT-A injection helped
to reduce pain and increase range of motion in young patients
with pain and stiffness after surgery for difficult and complex
complicated DDH cases, and in CP patients post hip surgery.
These findings appear to confirm previous reports of the role
of BoNT-A as a potentially effective adjunct therapy, which
could stabilize the condition and improve the quality of life
in CP and sport injury cases.12,14 The choice of muscles for
BoNT-A administration should be determined by clinical
examination looking for the painful muscles affected with
spasm and decrease range of motion. To increase the effective-
ness of BoNT-A it should be injected inside the fascial com-
partment in an appropriate dose and volume so the diffusion
occurs with minimizing unwanted spread.22
Following BoNT-A injection, a measurable goal should be
set to reach through multidisciplinary team; consisting of phys-
iotherapy, neurology and orthopedic surgery. This may in-
clude tight soft tissue stretching, activation of weak muscles
and re-educating the affected muscles reaching to functional
exercises that leads to return to normal function.12
To our knowledge, no previous study has shown the results
of BoNT-A in postoperative stiff hips in children. The limita-
tion of this study is the small number of the patients and the
lack of a control group.
Conclusion
The presented cases demonstrate that the preliminary results of
using BoNT-A are promising and it is a potentially rewarding
management option that could be considered in the manage-
ment of postoperative stiff hips in the pediatric age group, espe-
cially in difficult cases that are refractory to standard treatment.
It is recommended to recruit more patients to establish this line
of treating postoperative hip stiffness in children. Muscle selec-
tion, injection techniques and participation of all concerned
subspecialties utilizing appropriate modalities of treatment will
result in well-defined treatment goals and outcome.
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